Ipamorelin, a selective secretagogue, simultaneously activates the ghrelin receptor on the same pituitary cells, producing GH release through a completely different second pathway
Among the most promising non-incretin receptor targets are amylin (Amy) receptors (AMYRs), supported by data from phase I and phase II clinical trials showing efficacy of the long-acting amylin and calcitonin receptor agonist, cagrilinitide (Cagri), both as monotherapy 2,3 and in combination with the selective GLP-1R agonist, semaglutide 4,5
Dyspepsia, characterized by upper abdominal discomfort, early satiety, or postprandial fullness, may affect a similar proportion of patients and can contribute to reduced caloric intake and weight loss, though it may also impact quality of life if severe or persistent
Tylenol is one of the most relied-upon pain relievers in the country, yet few people stop to think about how the body breaks it down
Appraisal for the potential of viral and nonviral vectors in gene therapy: a review
Approximately 50% of women with galactorrhea have normal prolactin and the incidence of galactorrhea in hyperprolactinemic patients is between 30% and 80%
